1. Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor.

    Bioorganic & Medicinal Chemistry Letters 19(20):5945 (2009) PMID 19733067

    We herein report the discovery of a novel class of antagonists of the human adenosine A2B receptor. This low molecular weight scaffold has been optimized to offer derivatives with potential utility for the alleviation of conditions associated with this receptor subtype, such as nociception, diab...
  2. Discovery and optimization of potent and selective functional antagonists of the human adenosine A2Breceptor

    Bioorganic & Medicinal Chemistry Letters 19(20):5945 (2009) PMID 19733067

    A novel class of antagonists of the human adenosine A 2B receptor is described. Offering interesting pharmacokinetic properties, these derivatives may prove useful in elucidating the role of adenosine A 2B receptors in a number of human disease conditions.
  3. Discovery and optimization of potent and selective functional antagonists of the human adenosine A2Breceptor

    Bioorganic & Medicinal Chemistry Letters 19(20):5945 (2009)

    A novel class of antagonists of the human adenosine A 2B receptor is described. Offering interesting pharmacokinetic properties, these derivatives may prove useful in elucidating the role of adenosine A 2B receptors in a number of human disease conditions.
  4. Discovery and optimization of potent and selective functional antagonists of the human adenosine A2Breceptor

    Bioorganic & Medicinal Chemistry Letters 19(20):5945 (2009) PMID 19733067

    A novel class of antagonists of the human adenosine A 2B receptor is described. Offering interesting pharmacokinetic properties, these derivatives may prove useful in elucidating the role of adenosine A 2B receptors in a number of human disease conditions.
  5. Informatics and modeling challenges in fragment-based drug discovery.

    Current Opinion in Drug Discovery & Development 10(3):289 (2007) PMID 17554855

    This review summarizes recent developments in fragment-based drug-discovery methods with an emphasis on informatics and modeling requirements. Fragment-based methods have become established as a powerful approach in structure-based lead discovery. A number of successful projects have been announ...
  6. Informatics and modeling challenges in fragment-based drug discovery.

    Current Opinion in Drug Discovery & Development 10(3):289 (2007) PMID 17554855

    This review summarizes recent developments in fragment-based drug-discovery methods with an emphasis on informatics and modeling requirements. Fragment-based methods have become established as a powerful approach in structure-based lead discovery. A number of successful projects have been announ...
  7. The SeeDs approach: integrating fragments into drug discovery.

    Current Topics in Medicinal Chemistry 7(16):1568 (2007) PMID 17979768

    Finding novel compounds as starting points for optimization is a major challenge in drug discovery research. Fragment-based methods have emerged in the past ten years as an effective way to sample chemical diversity with a limited number of low molecular weight compounds. The structures of the f...
  8. The SeeDs approach: integrating fragments into drug discovery.

    Current Topics in Medicinal Chemistry 7(16):1568 (2007) PMID 17979768

    Finding novel compounds as starting points for optimization is a major challenge in drug discovery research. Fragment-based methods have emerged in the past ten years as an effective way to sample chemical diversity with a limited number of low molecular weight compounds. The structures of the f...
  9. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.

    Journal of Medicinal Chemistry 47(21):5085 (2004) PMID 15456252

    The binding of S100B to p53 down-regulates wild-type p53 tumor suppressor activity in cancer cells such as malignant melanoma, so a search for small molecules that bind S100B and prevent S100B-p53 complex formation was undertaken. Chemical databases were computationally searched for potential in...
  10. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.

    Journal of Medicinal Chemistry 47(21):5085 (2004) PMID 15456252

    The binding of S100B to p53 down-regulates wild-type p53 tumor suppressor activity in cancer cells such as malignant melanoma, so a search for small molecules that bind S100B and prevent S100B-p53 complex formation was undertaken. Chemical databases were computationally searched for potential in...